肿瘤免疫治疗的新视角:T细胞代谢调控OA北大核心

Despite the remarkable clinical efficacy achieved by immune checkpoint blockade(ICB)and adoptive T cell therapy,the majority of patients with solid tumors still fail to achieve long-term responses to immunotherapy.One important reason is the complex metabolic patterns and inhibitory signals within the tumor microenvironment(TME),which induce metabolic reprogramming in immune cells and thereby impair their anti-tumor efficacy.This review summarizes the metabolic preferences of CD8+T cells across various differentiation states,explores the metabolic changes that occur during their interaction with tumor cells and the TME,and discusses how these metabolic changes affect differentiation,function,and stemness of CD8+T cells.Additionally,strategies that target metabolic molecules or pathways are highlighted to enhance the antitumor ability of CD8+T cells,thereby improving the efficacy of chimeric antigen receptor gene-modified T lymphocyte(CAR-T cell)immunotherapy and ICB therapy.